Canbex Therapeutics

Canbex Therapeutics is dedicated to the development of novel compounds for the treatment of spasticity in multiple sclerosis (MS) and potentially other disorders. The goal of the Canbex program is to set a new standard in the treatment of spasticity, through improved tolerability. Canbex Therapeutics is based in London, UK.

Latest News Entry
Canbex Therapeutics announces start of Phase II trial of VSN16R for spasticity

Canbex Therapeutics Ltd today announced that its novel orally active medication for the treatment of spasticity, VSN16R, has entered a Phase II trial in patients with spasticity

Canbex Therapeutics enters into option agreement with Ipsen

Ipsen (Euronext: IPN; ADR: IPSEY) and Canbex Therapeutics Ltd (Canbex) today announced that Canbex has granted ...

all portfolio news